Michel Bolla

Summary

Affiliation: CHU de Grenoble
Country: France

Publications

  1. ncbi request reprint [Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer]
    Michel Bolla
    Département de cancérologie hématologie, Service d Urologie, Centre Hospitalier Universitaire, BP 392, 63011 Grenoble
    Bull Cancer 93:1101-5. 2006
  2. ncbi request reprint Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials
    M Bolla
    EORTC Radiotherapy and Genito Urinary Cooperative Groups, EORTC Data Center, Brussels, Belgium
    Front Radiat Ther Oncol 36:81-6. 2002
  3. ncbi request reprint Guidelines for primary radiotherapy of patients with prostate cancer
    Dirk Boehmer
    Klinik f Strahlentherapie, Universitatsmedizin Berlin, Charite Campus Mitte, Germany
    Radiother Oncol 79:259-69. 2006
  4. ncbi request reprint Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group
    Philip Poortmans
    Department of Radiotherapy, Dr B Verbeeten Institute, Tilburg, The Netherlands
    Radiother Oncol 84:121-7. 2007
  5. doi request reprint High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy
    Michel Bolla
    Clinique Universitaire de Cancérologie Radiothérapie, Grenoble, France
    Curr Opin Urol 23:349-54. 2013
  6. doi request reprint Combined hormone therapy and radiation therapy for locally advanced prostate cancer
    M Bolla
    Radiation Oncology Department, C H U Michallon, Grenoble Cedex 9, France
    Crit Rev Oncol Hematol 84:e30-4. 2012
  7. doi request reprint Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
    Michel Bolla
    Department of Radiation Oncology, Centre Hospitalier Universitaire A Michallon, Grenoble, France
    Lancet 380:2018-27. 2012
  8. pmc Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study
    David Knobel
    Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    BMC Cancer 6:118. 2006
  9. doi request reprint Duration of androgen suppression in the treatment of prostate cancer
    Michel Bolla
    Centre Hospitalier Regional Universitaire de Grenoble, Grenoble, France
    N Engl J Med 360:2516-27. 2009
  10. ncbi request reprint [The actions of the French Society of Radiation Oncology (SFRO), within the frame of Plan cancer and the recent events of radioprotection]
    M Bolla
    Département de cancérologie hématologie, Centre Hospitalier Universitaire de Grenoble, 38700, La Tronche, France
    Cancer Radiother 11:305-8. 2007

Detail Information

Publications61

  1. ncbi request reprint [Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer]
    Michel Bolla
    Département de cancérologie hématologie, Service d Urologie, Centre Hospitalier Universitaire, BP 392, 63011 Grenoble
    Bull Cancer 93:1101-5. 2006
    ..Very high risk prostate cancers, T3-4 N0 M0 or pelvic lymph node involvement (c or pN1) whatever the UICC T stage, need a long term androgen suppression of 3 years or more...
  2. ncbi request reprint Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials
    M Bolla
    EORTC Radiotherapy and Genito Urinary Cooperative Groups, EORTC Data Center, Brussels, Belgium
    Front Radiat Ther Oncol 36:81-6. 2002
  3. ncbi request reprint Guidelines for primary radiotherapy of patients with prostate cancer
    Dirk Boehmer
    Klinik f Strahlentherapie, Universitatsmedizin Berlin, Charite Campus Mitte, Germany
    Radiother Oncol 79:259-69. 2006
    ....
  4. ncbi request reprint Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group
    Philip Poortmans
    Department of Radiotherapy, Dr B Verbeeten Institute, Tilburg, The Netherlands
    Radiother Oncol 84:121-7. 2007
    ....
  5. doi request reprint High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy
    Michel Bolla
    Clinique Universitaire de Cancérologie Radiothérapie, Grenoble, France
    Curr Opin Urol 23:349-54. 2013
    ....
  6. doi request reprint Combined hormone therapy and radiation therapy for locally advanced prostate cancer
    M Bolla
    Radiation Oncology Department, C H U Michallon, Grenoble Cedex 9, France
    Crit Rev Oncol Hematol 84:e30-4. 2012
    ..5-3 years) improved significantly overall survival...
  7. doi request reprint Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
    Michel Bolla
    Department of Radiation Oncology, Centre Hospitalier Universitaire A Michallon, Grenoble, France
    Lancet 380:2018-27. 2012
    ....
  8. pmc Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study
    David Knobel
    Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    BMC Cancer 6:118. 2006
    ..Therefore, in this large retrospective study, we wanted to assess the outcome, prognostic factors, and the optimal RT dose in patients with SP...
  9. doi request reprint Duration of androgen suppression in the treatment of prostate cancer
    Michel Bolla
    Centre Hospitalier Regional Universitaire de Grenoble, Grenoble, France
    N Engl J Med 360:2516-27. 2009
    ..We compared the use of radiotherapy plus short-term androgen suppression with the use of radiotherapy plus long-term androgen suppression in the treatment of locally advanced prostate cancer...
  10. ncbi request reprint [The actions of the French Society of Radiation Oncology (SFRO), within the frame of Plan cancer and the recent events of radioprotection]
    M Bolla
    Département de cancérologie hématologie, Centre Hospitalier Universitaire de Grenoble, 38700, La Tronche, France
    Cancer Radiother 11:305-8. 2007
    ..We report on the actions the SFRO has participated with, or initiated these last 2 years...
  11. ncbi request reprint Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)
    Michel Bolla
    Department of Radiation Oncology, Centre Hospitalier Universitaire A Michallon, Grenoble, France
    Lancet 366:572-8. 2005
    ..We did a randomised controlled trial to compare radical prostatectomy followed by immediate external irradiation with prostatectomy alone for patients with positive surgical margin or pT3 prostate cancer...
  12. doi request reprint [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions]
    M Bolla
    Pôle de Cancérologie, Clinique Universitaire de Cancérologie Radiothérapie, Centre Hospitalier Universitaire de Grenoble, BP 217, 38043 Grenoble Cedex 9, France
    Cancer Radiother 14:510-4. 2010
    ..Complete androgen blockade with a four to six months duration, combined with external irradiation, enhanced the overall survival in patients with intermediate or poor risk localized prostate cancer...
  13. doi request reprint External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
    Michel Bolla
    Radiotherapy Department, University Hospital, Grenoble, France
    Lancet Oncol 11:1066-73. 2010
    ..In this report, we present the 10-year results...
  14. doi request reprint [Report of the mission commissioned by the Ministry of Health to the French Society of Radiation Oncology]
    M Bolla
    Département de cancérologie radiothérapie, Centre Hospitalier Regional Universitaire de Grenoble, Clinique Universitaire de Cancérologie Radiothérapie, 38000 Grenoble, France
    Cancer Radiother 13:190-4. 2009
    ..Due to the numerous actions of the roadmap managed by the tutelages, the aim of the mission was focused on the modalities of work of the professionals linked to radiotherapy: radiation oncologists, radiographers and physicists...
  15. ncbi request reprint [Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression]
    M Bolla
    Département de cancérologie radiothérapie, CHU de Grenoble, Hopital Albert Michallon, BP 217, 38043, Grenoble Cedex 09, France
    Cancer Radiother 11:363-9. 2007
    ..Local failure after radiotherapy can arise with cancer extending beyond the capsule and/or involvement of seminal vesicles or positive surgical margins...
  16. doi request reprint [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer]
    M Bolla
    Clinique Universitaire de Cancérologie Radiothérapie, Centre Hospitalier Universitaire, Grenoble, France
    Bull Cancer 95:1213-8. 2008
    ..Some trials, which have a long follow-up show that the risk of cardiovascular death is not significantly increased by hormonal treatment...
  17. ncbi request reprint Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer
    Michel Bolla
    Department of Radiation Oncology, Albert Michallon University Hospital, Grenoble, France
    BJU Int 100:44-7. 2007
  18. ncbi request reprint Fast growing cervical carcinomas. A retrospective analysis of 20 IB-IIB FIGO
    M Bolla
    Radiation Oncology Department, Hopital A Michallon, BP 217X, 38043, Grenoble, France
    Eur J Obstet Gynecol Reprod Biol 90:81-5. 2000
    ..This retrospective analysis is aimed at assessing 5-year outcomes...
  19. ncbi request reprint Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)
    Laurence Collette
    European Organisation for Research and Treatment of Cancer EORTC Data Center Biostatistics, Avenue E Mounier 83 11, B 1200, Brussels, Belgium
    Eur J Cancer 41:2662-72. 2005
    ..Postoperative irradiation improved biochemical progression-free survival in all patient groups. Longer follow-up is needed to assess the endpoint of clinical progression-free survival...
  20. ncbi request reprint Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
    Michel Bolla
    University Hospital, Grenoble, France
    Lancet 360:103-6. 2002
    ....
  21. doi request reprint Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial
    Michel Bolla
    Department of Oncology Radiotherapy, Centre Hospitalier Universitaire, Grenoble, France
    Radiother Oncol 97:312-7. 2010
    ..We evaluate the feasibility of concomitant and adjuvant docetaxel combined with three-dimensional conformal radiotherapy (3D-CRT) and androgen deprivation in high-risk prostate carcinomas...
  22. ncbi request reprint Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run
    Vassilis E Kouloulias
    EORTC, Data Center, Av Mounier 83, B 1200, Brussels, Belgium
    Radiother Oncol 73:11-20. 2004
    ..A dummy run was established to assess centre compliance to the radiotherapy protocol...
  23. ncbi request reprint Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer
    N Neymark
    EORTC Health Economics Unit, Brussels, Belgium
    Health Econ 11:233-48. 2002
    ..We show that the exact results of the economic evaluation are decisively determined by the restriction time point chosen and the approach taken to estimate mean survival time...
  24. doi request reprint Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'
    Sandra Collette
    Statistics Department, EORTC Headquarters, Brussels, Belgium
    Eur J Cancer 44:2587-99. 2008
    ..01) if WBI was given with >6 MV photons. The c-index was around 0.62. Nomograms with these factors are proposed to forecast the long-term risk of moderate or severe fibrosis...
  25. doi request reprint Development of a novel robot for transperineal needle based interventions: focal therapy, brachytherapy and prostate biopsies
    Jean Alexandre Long
    Urology Department, Grenoble University Hospital, Grenoble, France
    J Urol 188:1369-74. 2012
    ..Its ability to track prostate motion intraoperatively allows it to manage motions and guide needles to predefined targets...
  26. ncbi request reprint [Indications of the association of radiotherapy and hormonal treatment in prostate cancer]
    Michel Bolla
    Département de cancérologie hématologie, CHU de Grenoble, France
    Cancer Radiother 9:394-8. 2005
    ..The role of hormonal treatment is currently assessed in localized prostate cancer (T1-2 N0) with poor prognostic factors: Gleason score 8-10, PSA>20 ng/ml...
  27. ncbi request reprint Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer
    M Bolla
    Service de Radiotherapie, Centre Hospitalier Regional et Universitaire, Grenoble, France
    Eur Urol 35:23-5; discussion 26. 1999
    ..Long-term results of radiotherapy in locally advanced prostate cancer are poor due to local and distant failures. Since prostate cancer is hormone dependent, tumor androgen deprivation may enhance tumor eradication...
  28. doi request reprint Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)
    Oscar Matzinger
    European Organisation for Research and Treatment of Cancer EORTC, Headquarters, Brussels, Belgium
    Acta Oncol 49:24-34. 2010
    ..We present the toxicity reported until year 3 after treatment...
  29. ncbi request reprint Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis
    N Neymark
    EORTC Health Economics Unit, Avenue E Mounier 83, Bte 11, B 1200, Brussels, Belgium
    Eur J Cancer 37:1768-74. 2001
    ....
  30. ncbi request reprint Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863
    Fatma Ataman
    EORTC Data Center, Radiotherapy Group, Avenue E Mounier 83, Bte 11, B 1200 Brussels, Belgium
    Eur J Cancer 40:1674-81. 2004
    ..Although four treatment-related deaths (1%) occurred, grade 3 or 4 late complications were less than 5%...
  31. ncbi request reprint [Combined induction chemotherapy and radiotherapy in case of undifferentiated carcinoma of nasopharynx tumours (UCNT)]
    Ch A Righini
    CHU A Michallon, Service d ORL et de Chirurgie Cervico faciale, 38043 Grenoble 09, France
    Rev Laryngol Otol Rhinol (Bord) 127:223-8. 2006
    ..The objectives of our study were to consider the morbidity and the effectiveness of combined induction chemotherapy and radiotherapy in the treatment of Undifferentiated Carcinoma of Nasopharynx Tumor (UCNT)...
  32. ncbi request reprint [Quantification of prostate movements during radiotherapy]
    X Artignan
    Service de Radiotherapie, CHU de Grenoble, Boulevard de la Chantourne, 38700 La Tronche, France
    Cancer Radiother 10:381-7. 2006
    ..Ideally, real time imaging tools should allow an accurate localisation of the prostate and the adaptation of the dosimetry before each treatment session in a time envelope not exceeding 20 minutes...
  33. ncbi request reprint [Retrospective analysis of 108 ductal carcinomas in situ of the breast treated by radiosurgery association]
    P Fourneret
    Service de cancérologie radiothérapie, CHU de Grenoble, 38043 Grenoble Cedex 09, France
    Cancer Radiother 10:550-8. 2006
    ..To evaluate survival and prognostic factors of 108 patients with clinically or mammographically detected ductal carcinoma in situ (DCIS), treated from 1980 to 1996 by complete local excision followed by external irradiation...
  34. ncbi request reprint [Transmandibular buccopharyngectomy after radiotherapy for orpharyngeal cancer]
    O Cuisnier
    CHU de Grenoble, Service ORL, BP 217, 38100 Grenoble, France
    Rev Laryngol Otol Rhinol (Bord) 123:17-22. 2002
    ..We present a retrospective study of 95 patients with recurrence of oropharyngeal carcinoma after exclusive radiotherapy. The treatment consisted in a salvage composite resection in all cases...
  35. ncbi request reprint Prognostic factors for survival in adult patients with cerebral low-grade glioma
    Francesco Pignatti
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Clin Oncol 20:2076-84. 2002
    ..To identify prognostic factors for survival in adult patients with cerebral low-grade glioma (LGG), to derive a prognostic scoring system, and to validate results using an independent data set...
  36. ncbi request reprint Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863
    A Zurlo
    EORTC Data Center, Avenue E Mounier 83, 1200, Brussels, Belgium
    Eur Urol 42:125-32. 2002
    ....
  37. ncbi request reprint The use of a semi-customized phantom for verification of conformal plans
    J Y Giraud
    CHU de Grenoble, service d oncologie radiothérapie, Grenoble, France
    Med Dosim 24:183-8. 1999
    ..Our phantom and the Fricke gel solution are convenient to carry out validation of conformal treatments...
  38. doi request reprint Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: results of the Dummy Run procedure
    Paul A Fenton
    EORTC Headquarters, Brussels, Belgium
    Radiother Oncol 107:346-51. 2013
    ..As part of the quality assurance of radiotherapy (QART) a Dummy Run (DR) procedure was performed...
  39. ncbi request reprint Prognostic assessment of PTK activity in T1-T2, N0-N1, M0 breast cancer: a multicentric retrospective study
    Béatrice Rostaing-Puissant
    Laboratoire de Biochimie A, CHU A Michallon, Grenoble, France
    Breast Cancer Res Treat 74:135-41. 2002
    ....
  40. doi request reprint [Multidisciplinary team meetings in cancerology: setting priorities for improvement]
    Pascale Guillem
    CHU de Grenoble, centre de coordination en cancérologie, France
    Bull Cancer 98:989-98. 2011
    ..Leading to completeness raises questions about medical time employment and meaning of the MDT meeting for standard clinical cases. The priority seems to enforce multidisciplinarity rather than reach completeness...
  41. doi request reprint Can the sentinel lymph node technique affect decisions to offer internal mammary chain irradiation?
    Jean Cyril Bourre
    Nuclear Medicine Department, Grenoble University Hospital, La Tronche, France
    Eur J Nucl Med Mol Imaging 36:758-64. 2009
    ....
  42. ncbi request reprint Moisture content of Hemoccult slides influences test sensitivity
    Henri Faure
    Département de Biologie Intégrée, CHU La Tronche, Grenoble, France
    Eur J Gastroenterol Hepatol 15:1111-4. 2003
    ..In this paper, we show that the moisture content of Hemoccult slides influences test sensitivity...
  43. ncbi request reprint Patient setup optimization for external conformal radiotherapy
    J Troccaz
    TIMC IMAG, Faculte de Medecine, La Tronche, France
    J Image Guid Surg 1:113-20. 1995
    ..This system is under clinical evaluation...
  44. ncbi request reprint [Absorbed dose during helical acquisition CT. Effect of acquisition parameters]
    J Y Giraud
    Service de cancérologie radiothérapie, CHU de Grenoble, BP 217, 38043 Grenoble Cedex
    J Radiol 82:45-50. 2001
    ..In order to prepare for implementation of this new regulation, we have studied the dose delivered during spiral CT acquisition...
  45. ncbi request reprint MRI/TRUS data fusion for brachytherapy
    V Daanen
    TIMC Laboratory, Grenoble, France
    Int J Med Robot 2:256-61. 2006
    ..Because ultrasound imaging is patient- and operator-dependent, we have proposed to fuse MRI data to TRUS data to make image processing more reliable. The technical accuracy of this approach has already been evaluated...
  46. ncbi request reprint Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run
    J Bernard Davis
    Radiation Oncology, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland
    Radiother Oncol 64:65-73. 2002
    ..A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial...
  47. ncbi request reprint [Yield of colonoscopy by indication and consequences for colorectal polyp and cancer screening: a prospective survey in Isère, France]
    Catherine Exbrayat
    Office Départemental de Lutte contre le Cancer, 38244 Meylan, France
    Gastroenterol Clin Biol 26:225-30. 2002
    ....
  48. ncbi request reprint Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
    Jacques Bernier
    Department of Radio Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    N Engl J Med 350:1945-52. 2004
    ..We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head and neck cancer...
  49. ncbi request reprint EAU guidelines on prostate cancer
    Axel Heidenreich
    Department of Urology, University Hospital Cologne, Cologne, Germany
    Eur Urol 53:68-80. 2008
    ..To present a summary of the 2007 version of the European Association of Urology (EAU) guidelines on prostate cancer (PCa)...
  50. ncbi request reprint Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911
    Theodorus H van der Kwast
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and University Health Network, Toronto, Canada
    J Clin Oncol 25:4178-86. 2007
    ..Review pathology data of specimens from participants in this trial were analyzed to identify which factors predict increased benefit from adjuvant radiotherapy...
  51. ncbi request reprint High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991
    Fatma Ataman
    EORTC Data Centre, Radiotherapy Group 83 Avenue Mounier, Bte 11, B 1200 Brussels, Belgium
    Eur J Cancer 40:2411-6. 2004
    ..The technology questionnaire is the first step in the extensive quality assurance programme dedicated to this high-tech radiotherapy trial...
  52. ncbi request reprint Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients
    Mahmut Ozsahin
    Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Int J Radiat Oncol Biol Phys 64:210-7. 2006
    ..To assess the outcomes and patterns of failure in solitary plasmacytoma (SP)...
  53. ncbi request reprint [Breast carcinoma with predominant neuroendocrine differentiation]
    Sophie Frachon
    Service d Anatomie et Cytologie Pathologiques, CHU, Grenoble
    Ann Pathol 24:278-83. 2004
    ..We discuss the histogenesis of composite mammary carcinomas with neuroendocrine differentiation, the outcome of each component and the prognostic relevance of such a diagnosis...
  54. ncbi request reprint Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 109:2004-10. 2007
    ....
  55. ncbi request reprint Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer
    Theodorus H van der Kwast
    J Clin Oncol 25:5671-2. 2007
  56. ncbi request reprint Course and prognosis of basaloid squamous cell carcinoma of the head and neck: a case-control study of 62 patients
    Edouard Soriano
    Department of ENT HNS, University Medical Center of Grenoble, 38043 Grenoble Cedex 09, France
    Eur J Cancer 44:244-50. 2008
    ..To describe the natural history and evaluate the prognosis of basaloid squamous cell carcinoma (BSCC) of the upper aero-digestive tract as compared to the usual squamous cell carcinoma (SCC)...
  57. ncbi request reprint Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911)
    Theodorus H van der Kwast
    Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada, and Department of Urology, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Virchows Arch 449:428-34. 2006
    ..05 and p>0.8). The observations suggest that review of pathological stage and surgical margin of radical prostatectomy strongly improves their prognostic impact in multi-institutional studies or trials...
  58. ncbi request reprint MRI/TRUS data fusion for prostate brachytherapy. Preliminary results
    Christophe Reynier
    TIMC Laboratory, School of Medicine, F 38706 La Tronche, France
    Med Phys 31:1568-75. 2004
    ..This may significantly modify prostate volume definition and have an impact on treatment planning...
  59. ncbi request reprint Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network
    Guilhem Bousquet
    Oscar Lambret Anti Cancer Center, 3 Rue Frederic Combemale, Lille, France
    Radiother Oncol 85:355-61. 2007
    ..Breast sarcoma (BS) is a rare tumour. While surgical resection is the primary treatment, the role of radiation therapy (RT) and chemotherapy remains unclear. This study aimed at defining prognostic factors and treatment strategies...
  60. doi request reprint Clinical stage T3 prostate cancer: the added value of three-dimensional conformal/intensity-modulated external-beam radiotherapy
    Michel Bolla
    Eur Urol 53:1104-6; discussion 1106-8. 2008
  61. doi request reprint Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder
    Philip M Poortmans
    Department of Radiation Oncology, Dr Bernard Verbeeten Institute, Tilburg, The Netherlands
    Acta Oncol 47:937-40. 2008
    ..We prospectively evaluated concomitant radiotherapy and chemotherapy for advanced bladder cancer in a phase II EORTC trial to test whether it could be further studied as a potential treatment of bladder cancer...